Skip to content
Wholesale trade
KZActiveBIN 110940020405
Plans from 2 000 ₸ a month
No entries in risk registers
Registers checked: 17
To risks

ТОО "UMID-PHARM"

Director
Арипов Эльдар Хикматович
Incorporated
28.09.2011
Address
Шымкент мкр. ТУЛПАР, ДОМ.75, КВ.2
РНН
582300017000

This is a company preview

Unlock the full report for 1 check — contacts, bank accounts, court cases, government contracts, arrests, licenses and PDF export.

The pack is not a subscription, its checks last 30 days

Risks

0/17

This assessment is informational and analytical only, based on our internal methodology and open sources; it is not an official government conclusion or a guarantee of reliability.

Procurement signals

Court cases

Arrests & encumbrances

Enforcement proceedings

Certificates

Licenses

Profile

Summary

Full name
ТОВАРИЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "UMID-PHARM"
BIN
110940020405
Status
Active
Director
Арипов Эльдар Хикматович
Registration date
28.09.2011
Activity
Оптовая реализация фармацевтических и медицинских товаров в рамках гарантированного объема бесплатной медицинской помощи
Legal address
Шымкент мкр. ТУЛПАР, ДОМ.75, КВ.2

In government contracts over 2 years

VAT payer
Yes, since 01.02.2012
КАТО
791110000
РНН
582300017000
КФС
Собственность предприятий без государственного и иностранного участия
КСЕ
Национальные частные нефинансовые корпорации – ОПП
Company size
Малые предприятия
Employees
от 0 до 5 чел.
Procurement role
Поставщик

Activities

1
46462primary

Оптовая реализация фармацевтических и медицинских товаров в рамках гарантированного объема бесплатной медицинской помощи

Download

Contacts

Change history

Financials

Tax payments

6

By year · ₸

2026
24.4M
2025
11.4M+8%
2024
10.5M-61%
2023
26.7M+13%
2022
23.6M+361%
2021
5.1M
·24.4M
2026year to date
+8%11.4M
2025
-61%10.5M
2024
+13%26.7M
2023
+361%23.6M
2022
·5.1M
2021
2026
Tax paid24,443,869 ₸
Penalty55,700 ₸
Fine0 ₸
VAT refund0 ₸
2025
Tax paid11,353,047 ₸
Penalty42,046 ₸
Fine235,920 ₸
VAT refund0 ₸
2024
Tax paid10,519,652 ₸
Penalty372,240 ₸
Fine0 ₸
VAT refund0 ₸
2023
Tax paid26,706,391 ₸
Penalty508,334 ₸
Fine0 ₸
VAT refund0 ₸
2022
Tax paid23,645,518 ₸
Penalty624,920 ₸
Fine30,630 ₸
VAT refund0 ₸
2021
Tax paid5,125,720 ₸
Penalty30,350 ₸
Fine0 ₸
VAT refund0 ₸
Estimated taxable profit

Estimate: corporate income tax ÷ 0%. Not a filing and not revenue — the taxable profit implied by the corporate income tax paid. Actual profit differs by deductions, carried-forward losses and reduced rates.

Download

Financial statements

Premium

Public contracts

What it sells and where

Samruk-Kazyna procurement

Tender bids

Procurement as a customer

Assets

Bank accounts

Management & owners

Leadership

1
  • АЭ

    Арипов Эльдар Хикматович

    Director

Download

Founders

Accreditations

Employees

Affiliated companies

Premium

Director's involvement in other legal entities

Branches

Relations & mentions

Company networks

Premium

Similar companies

Media mentions

Company summary

ТОО "UMID-PHARM" (BIN 110940020405) is an active legal entity in Шымкент, registered in 2011 (15 years on the market). Primary activity — оптовая реализация фармацевтических и медицинских товаров в рамках гарантированного объема бесплатной медицинской помощи. Per open government registries as of November 8, 2026: 836 government contracts on Портал государственных закупок РК (goszakup.gov.kz) worth 688,972,696 ₸. Automated screening of open registries found no risk indicators for "UMID-PHARM". Director on record — Арипов Эльдар Хикматович. Data current as of November 8, 2026.

Information is aggregated from open government registries of Kazakhstan: Министерство юстиции РК, Комитет государственных доходов МФ РК, Верховный Суд РК, Портал государственных закупок РК, АО «Самрук-Казына», Бюро национальной статистики РК, Портал электронного лицензирования. Data is indexed automatically and may lag behind primary sources; the absence of a record does not guarantee the absence of the corresponding facts. This is reference information and does not replace an official extract. Learn more about the methodology and sources — SafeDeal editorial policy.